Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India

 Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India

Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India

Shots:

  • Glenmark has received manufacturing and marketing approval for its antiviral drug FabiFlu (favipiravir) to treat COVID-19 in India. The drug will be available as a prescribed therapy for INR 103/tablet with recommended dose being 1800mg (bid) on day 1, followed by 800mg (bid) up to day 14
  • Favipiravir demonstrated clinical improvements of up to 88% in SARS-CoV-2 virus infection, with rapid reduction in viral load by 4 days across the age groups 20 to >90yrs., including in patients with co-morbid conditions like diabetes and heart disease suffering from mild to moderate COVID-19
  • The drug receives MHLW’s approval in 2014 to treat novel or re-emerging influenza virus infections. Additionally, the company has initiated clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India

Click here to read full press release/ article | Ref: Businesswire | Image: Bloomlive

Related News: Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post